ArkBio's ex-Roche antiviral hits primary goal in RSV phase 3

ArkBio's ex-Roche antiviral hits primary goal in RSV phase 3, sparking race to regulator and wait for more data

Ark Biopharmaceutical’s bet on one of the less congested parts of the respiratory syncytial virus (RSV) space has delivered phase 3 results.

Related Keywords

, Roche , Rsv , Antiviral , Clinical Trial Data , China , Clinical Data , Biotech , Fierce Biotech Homepage ,